Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
23.51
+0.24 (1.03%)
Oct 2, 2026, 4:00 PM EDT - Market closed
Apollomics Revenue
In the year 2025, Apollomics had annual revenue of $8.84M with 776.31% growth. Apollomics had revenue of $342.00K in the half year ending December 31, 2025, with 2.70% growth.
Revenue (ttm)
$8.84M
Revenue Growth
+776.31%
P/S Ratio
5.84
Revenue / Employee
$631,571
Employees
14
Market Cap
51.63M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.84M | 7.83M | 776.31% |
| Dec 31, 2024 | 1.01M | 545.00K | 117.46% |
| Dec 31, 2023 | 464.00K | -552.00K | -54.33% |
| Dec 31, 2022 | 1.02M | 1.01M | 50,700.00% |
| Dec 31, 2021 | 2.00K | -1.84M | -99.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 34.59M |
| Celularity | 18.97M |
| ImageneBio | 800.00K |
| Serina Therapeutics | 130.00K |
| INmune Bio | 50.00K |
| eXoZymes | -700.00 |
APLM News
- 6 weeks ago - Apollomics announces $10M private placement transaction - TheFly
- 7 weeks ago - Apollomics Announces $10 Million Private Placement Transaction - GlobeNewsWire
- 2 months ago - Apollomics Inc trading resumes - TheFly
- 2 months ago - Apollomics Inc trading halted, volatility trading pause - TheFly
- 2 months ago - Apollomics regains compliance with Nasdaq listing requirements - TheFly
- 2 months ago - Apollomics Regains Full Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 3 months ago - Apollomics Inc trading resumes - TheFly
- 3 months ago - Apollomics Inc trading halted, volatility trading pause - TheFly